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Prognostic Importance of Myocardial Injury in Critically Ill Dogs
with Systemic Inflammation
R. Langhorn, M.A. Oyama, L.G. King, M.C. Machen, D.J. Trafny, V. Thawley, J.L. Willesen,
I. Tarnow, and M. Kjelgaard-Hansen
Background: In noncardiac critical disease in humans, myocardial injury as detected by cardiac troponin I and T (cTnI
and cTnT) has been linked to high intensive care unit (ICU) death independent of prognostic composite scoring.
Hypothesis: Presence of myocardial injury predicts short-term death in critically ill dogs with systemic inﬂammation
and provides additional prognostic information when combined with established canine prognostic composite scores.
Animals: Forty-two dogs admitted to the ICU with evidence of systemic inﬂammation and no primary cardiac disease.
Methods: Prospective cohort study. Blood samples were obtained at ICU admission for the measurement of cTnI and
cTnT, C-reactive protein, and several cytokines. The acute patient physiologic and laboratory evaluation (APPLE) score
and the survival prediction index were calculated within the ﬁrst 24 hours of admission. Receiver operating characteristic
(ROC) curves were used to examine the prognostic capacity of each biomarker and severity score. Multiple logistic regres-
sion analysis was performed to evaluate whether cardiac markers signiﬁcantly contributed to severity scores.
Results: Twenty-eight day case fatality rate was 26% (11/42 dogs). cTnI concentrations were (median [range]) 0.416
[0.004–141.5] ng/mL and cTnT concentrations were 13.5 [<13–3,744] ng/L. cTnI, cTnT, and the APPLE score were all sig-
niﬁcant prognosticators with areas under the ROC curves [95% CI] of 0.801 [0.649; 0.907], 0.790 [0.637; 0.900], and 0.776
[0.621; 0.889], respectively. cTnI signiﬁcantly contributed to the APPLE score in providing additional prognostic speciﬁcity
(P = .025).
Conclusions and Clinical Importance: Markers of myocardial injury predict short-term death in dogs with systemic
inﬂammation and cTnI signiﬁcantly contributes to the APPLE score.
Key words: Biomarker; Cardiac troponin; Companion animals; Severity scores.
Critical illness can be deﬁned as important meta-bolic derangements that require intensive care to
sustain life or enhance metabolic stability.1 Critically
ill patients have a high risk of death, and the ability
to measure markers of deterioration is crucial as it
could allow the possibility to intervene with additional
or alternate treatment. Prognostic composite scores
are continuously being examined and developed in
human2 and veterinary medicine, with main components
being markers of organ dysfunction. Two diagnosis-
independent severity scores have been validated for use
in dogs, the acute patient physiologic and laboratory
evaluation (APPLE)3 and the survival prediction index
(SPI2).4 These scores, however, do not contain any
markers of myocardial injury, and contribution of
such injury to the prognostic capacity of severity
scores in dogs is unexplored.
In humans, cardiac troponins I and T (cTnI and
cTnT) have long been recognized as sensitive and
speciﬁc markers of myocardial injury which are most
commonly used in the diagnosis of acute myocardial
infarction (AMI).5 However, there is an increasing
awareness that myocardial injury occurs much more
frequently than previously suspected in critically ill
human patients with primary disease of noncardiac
origin.6–9 In the noncardiologic human ICU, sepsis is
the most common cause of death.10 Myocardial injury
in patients with sepsis or other causes of systemic
inﬂammation is presumably caused by hemodynamic
changes, toxic eﬀects of cytokines, microthrombosis,
and ischemia-reperfusion injury.7,11-14 This myocardial
injury, though often clinically unrecognized, has been
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AMI acute myocardial infarction
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MCP-1 monocyte chemo-attractant protein-1
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associated with increased morbidity and death,7–9,13,15
and detecting and treating it might be all the more
important as it might be caused by cardiomyocyte
leakage of the cytosolic pool of troponins rather than
cell necrosis, thereby being potentially reversible.6,16
Interestingly, no established correlation between car-
diac troponin concentrations and prognostic composite
scores in humans, such as the acute physiology and
chronic health evaluation (APACHE) II or III or the
simpliﬁed acute physiology score (SAPS) II, has been
found.7,12,13,17,18 As the signiﬁcance of myocardial
injury or dysfunction was not included when these
models were developed, this had led to speculation
that cardiac troponins can provide additional prognos-
tic information,7,13 and several human studies have
concluded that cardiac troponin remains an indepen-
dent prognosticator even after stratifying for degree of
illness severity.13,17 In dogs, the established prognostic
composite scores, APPLE and SPI2, also lack markers
of myocardial injury.
The objective of this study was to investigate the
presence and prognostic relevance of myocardial injury
in critically ill dogs with systemic inﬂammation. It was
hypothesized that the presence of myocardial injury
would be predictive of short-term mortality in dogs
admitted to the ICU with systemic inﬂammation, and
that it would provide additional prognostic informa-
tion when added to established prognostic composite
scores in dogs. As the myocardial injury is thought to
be mediated by inﬂammatory cytokines,6,14,16 a 2nd
objective of the study was to investigate the possible
contribution of cytokines to prognostic composite
models with an included marker of myocardial injury.
Materials and Methods
Study Population
Over a 3-month period from May to July 2011, critically ill cli-
ent-owned dogs were included at the time of admission to the ICU
at the Veterinary Hospital of the University of Pennsylvania
(VHUP). The study protocol was approved by the VHUP
Privately Owned Animal Protocol Committee and the University
of Pennsylvania Institutional Animal Care and Use Committee,
and informed consent was obtained from all owners. The study
was performed as a prospective cohort study with 28 days of fol-
low-up. Dogs that had been diagnosed with cardiac disease before
admission were excluded. An echocardiographic examination was
performed by a board-certiﬁed cardiologist or cardiology resident
and a 5-min EKG recorded. Dogs in which evidence of structural
primary heart disease (symptomatic or asymptomatic) was identi-
ﬁed were further excluded. Likewise, dogs recently treated with a
known cardiotoxic drug (eg, doxorubicin) were excluded. Finally,
dogs were excluded if data collection posed a risk to the dog (ie, if
the dog was too small for collection of the required blood volume,
had severe respiratory distress, or severe anemia), if study partici-
pation was declined by the owner or attending clinician, or if they
were euthanized for reasons other than a grave prognosis for sur-
vival (eg, ﬁnancial reasons).
Systemic inﬂammation at ICU admission was deﬁned as a
serum concentration of C-reactive protein (CRP) >35 mg/L
within the ﬁrst 24 hours of admission. Dogs with CRP concen-
trations below this cut-oﬀ were excluded from the study when
results of the CRP analysis were available. Based on clinical,
hematological, and biochemical ﬁndings, an SPI2 (a logistic
regression formula based on the parameters PCV, creatinine,
albumin, mean arterial pressure, respiratory rate, age, and admit-
ting service [medicine or surgery])4 and an APPLE (a scoring
system based on the parameters WBC, creatinine, total bilirubin,
albumin, lactate, Sp02, respiratory rate, age, mentation, and pres-
ence of ﬂuid in one or more body cavities) score3 were calculated
for each dog with systemic inﬂammation. Both were calculated
within 24 hours of ICU admission according to previously
described methods. Clinical outcome was deﬁned as survival or
mortality 28 days postadmission and was determined through
follow-up visits or telephone contact with the owner.
Healthy animals for a control group were recruited from hos-
pital staﬀ and veterinary students and determined healthy
through physical examination, hematological and biochemical
proﬁles, and echocardiography.
Blood Sampling and Analyses
For each dog, a hematological and biochemical analysis was
performed at the time of ICU admission with automated ana-
lyzers,b,c and cross checked by a board-certiﬁed clinical pathol-
ogist. Serum for analysis of cTnI, cTnT, and cytokines was
obtained at the time of ICU admission and for CRP analysis
at admission and 12–24 hours later. Serum was collected into
gel separator tubes, allowed to clot for 30 minutes at room
temperature, centrifuged for 10 minutes at 1,300 9 g, sepa-
rated, and stored in cryovials at 70°C within 2 hours of
blood collection. Samples were stored for a maximum of
8 months until batch analysis. cTnI and cTnT were analyzed
by commercially available high-sensitivity immunoassays.d,e
The cTnI assay has recently been validated for use in compan-
ion animals,19 and the cTnT assay has been used previously
for assessment of myocardial injury in dogs.20 CRP was ana-
lyzed by a commercially available turbidimetric immunoassay
validated for canine use21 and calibrated with puriﬁed canine
CRP.f Serum cytokine activity was assessed by a canine-spe-
ciﬁc tumor necrosis factor-a (TNF-a) assayg (detection limit:
2.4 pg/mL) and a canine-speciﬁc multiplex assayh for interleu-
kin-10 (IL-10) (detection limit: 1.6 pg/mL), IL-15 (detection
limit: 14.8 pg/mL), IL-18 (detection limit: 4.6 pg/mL), and
monocyte chemotactic protein-1 (MCP-1) (detection limit:
8.6 pg/mL) with an automated analyzer.i The assays included
internal quality control material.
Statistical Analyses
Data were assessed for normality by D’Agostino–Pearson
omnibus test. Logarithmic transformation was applied where this
assured a Gaussian distribution of otherwise nonparametric data.
A two-tailed t-test was used to compare Gaussian data, and the
Mann–Whitney U-test was used to compare non-Gaussian data.
In a few cases, because of the fact that all control dogs had cTnT
and IL-10 values below the detection limits of the assays, these
animals were set to have concentrations corresponding to the
detection limits, and the Wilcoxon Signed Rank test was used to
test the data against a hypothetical value (the cut-oﬀ value of the
assay in question). Correlations between cardiac markers, severity
scores, and cytokines were assessed graphically as well as by
Pearson’s or Spearman’s correlation coeﬃcient where appropri-
ate. The prognostic capability for 28-day mortality of the SPI2
and APPLE score models as well as of markers of cardiac injury
(cTnI and cTnT) were assessed by receiver operating characteris-
tic (ROC) curve analysis. A signiﬁcant prognosticator was
deﬁned as having an area under the curve (AUC) signiﬁcantly
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greater than 0.5. Where the AUC for a prognostic composite
score and for a cardiac marker was signiﬁcantly greater than 0.5,
the cardiac marker was added to the scoring model by multiple
logistic regression to determine whether it provided additional
prognostic information to the model. The optimal combination
of composite score and cardiac marker was obtained in a for-
ward inclusion fashion.22 To investigate the suggested mediation
of myocardial injury by inﬂammatory cytokines and its relation
to prognosis, ROC curves were also created for each cytokine
investigated, and those that had AUCs signiﬁcantly greater than
0.5 were then added into the model individually in a forward
inclusion fashion. Troponin and cytokine concentrations were
logarithmically transformed to achieve Gaussian distribution for
multiple logistic regression. Statistical signiﬁcance was deﬁned as
P < .05. All statistical analyses were conducted by commercial
statistical software (Normality, t-test, Mann–Whitney U-test,
Wilcoxon’s test, correlations,j ROC curve analysis,k and multiple
logistic regressionl).
Results
Study Population Characteristics
One hundred and six dogs were admitted to the
ICU during the study period. Of these, 39 were
excluded because of cardiac disease. Twelve dogs were
excluded because data collection posed a risk to the
animal, and four were excluded because the owner or
the attending clinician declined inclusion of the dogs.
Two dogs died in the ICU before inclusion in the
study. Of the remaining 49 dogs, six did not meet the
criteria of systemic inﬂammation at the time of admis-
sion and were excluded. In addition, 1 dog was
excluded because it was euthanized because of a grave
prognosis for mobility rather than a grave prognosis
for survival. Thus, the study population consisted of
42 dogs. The 42 dogs were 1 female intact, 20 female
spayed, and 21 male castrated dogs with an age span
of 1–14 years (mean 7.0 years). Eight dogs were mixed
breeds; all other dogs were purebreds of 23 diﬀerent
breeds, the most frequent being Labrador Retriever
(n = 6), Boxer (n = 3), and French Bulldog (n = 3).
Dogs presented with a primary diagnosis of trauma
(n = 10, 5 dogs with polytrauma and 5 dogs with
localized trauma), neoplasia (n = 8), gastrointestinal
disease (n = 8), respiratory disease (n = 5), neurologi-
cal disease (n = 4), hematological disease (n = 2), and
various (n = 5: hemoabdomen caused by rupture of
splenic hematoma [n = 2] and 1 of each of biliary
mucocele, peritonitis, and GDV) diseases.
Eight dogs were used as healthy controls. The
8 dogs were 4 female spayed, 2 male intact, and 2 male
castrated dogs with an age span of 1–9 years (mean
3.9 years). Two dogs were mixed breeds; all other dogs
were purebreds of 6 diﬀerent breeds.
Clinical Outcome
The 28-day case fatality rate was 26% (11/42 dogs).
Ten dogs were euthanized during hospitalization
because of the severity of clinical signs and perceived
poor prognosis, and 1 dog died at home after
discharge. One dog was lost to follow-up and was last
seen 21 days after admission. The owner could not be
reached after this date. As the dog was doing well on
day 21, it was considered a survivor.
Severity Scores, Cardiac Troponins, and Cytokines
The median [range] APPLE score of the 42 dogs
with systemic inﬂammation was 35 [16–54]. Nonsurvi-
vors (41 [16–54]) had signiﬁcantly higher APPLE
scores than survivors (31 [17–48]) (Mann–Whitney,
P = .0078). The median [range] SPI2 score was 0.71
[0.25–0.91]. There was no signiﬁcant diﬀerence between
SPI2 scores for survivors (0.72 [0.33–0.9]) and nonsur-
vivors (0.58 [0.25–0.91]) (Mann–Whitney, P = .11).
Admission cTnI concentrations were (median
[range]) 0.416 [0.004–141.5] ng/mL. Forty of the 42
dogs (95.2%), including all nonsurvivors, had cTnI
concentrations above the concentration range of the
control dogs (0.01 [0.004–0.04] ng/mL) at the time of
ICU admission. Nonsurvivors (2.64 [0.24–85.17]
ng/mL) had signiﬁcantly higher cTnI concentrations
than survivors (0.20 [0.004–141.5] ng/mL) (based on
ROC analysis) and control dogs (0.01 [0.004–0.04]
ng/mL) (t-test, P < .001), and survivors had signiﬁ-
cantly higher cTnI concentrations than control dogs
(t-test, P < .001) (Fig 1A). Admission cTnT concentra-
tions were 13.5 [<13–3,744] ng/L. Twenty-one dogs
(50%), including 10 of 11 (91%) nonsurvivors, had
cTnT concentrations above the detection limit of the
assay (13 ng/L). All healthy dogs had cTnT concentra-
tions below the detection limit. Nonsurvivors (46 [<13–
686] ng/L) had signiﬁcantly higher cTnT concentra-
tions than survivors (<13 [<13–3,744] ng/L) (based on
ROC analysis) and control dogs (all <13 ng/L) (Wilco-
xon Signed Rank test, P = .002), and survivors had
signiﬁcantly higher cTnT concentrations than control
dogs (Wilcoxon Signed Rank test, P = .001) (Fig 1B).
Admission cTnI and cTnT concentrations were highly
correlated (r = 0.91, Spearman, P < .001). No correla-
tion was found between the cardiac troponins and the
APPLE score (r = 0.20 [Spearman, P = .21] and
r = 0.28 [Spearman, P = .07] for correlation with cTnI
and cTnT, respectively) or the SPI2 (r = 0.11 [Spear-
man, P = .51] and r = 0.15 [Spearman, P = .35] for
correlation with cTnI and cTnT, respectively).
The APPLE score and both cardiac troponins were
found to be signiﬁcant prognosticators (Table 1).
However, no signiﬁcant prognostic capacity was identi-
ﬁed for SPI2 in the examined cohort (Table 1). It was,
therefore, not possible to investigate the signiﬁcance of
adding a marker of myocardial injury to this model.
The possible contribution of cardiac markers to the
APPLE score was examined by multiple logistic
regression. cTnI contributed signiﬁcantly (P = .025) in
a model combining the APPLE score and cTnI (coef-
ﬁcient estimate [95% CI]: 1.01 [0.04; 1.99]) corre-
sponding to an odds ratio of 28-day mortality of 2.7
for each 10-fold increase in cTnI. There was no signif-
icant contribution of cTnT to the APPLE score
(P = .16). Graphing the cTnI concentration against
the APPLE score revealed that both prognosticators
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had an excellent negative predictive value attributable
to high prognostic sensitivity, but a less optimal posi-
tive predictive value attributable to compromised
prognostic speciﬁcity (many false positives) when
applied alone. The combination of cTnI and APPLE
clearly reduced the number of false positives, and
cTnI thus seemed to improve the prognostic speciﬁcity
(and thereby the positive predictive value) of the
model (Fig 2). As all animals that died had cTnI
values above the optimal predictive cut-oﬀ (0.24
ng/mL) identiﬁed by the ROC analysis, the number
of true positives (nonsurvivors predicted to die)—and
thereby the prognostic sensitivity of the APPLE score—
was not compromised by the inclusion of cTnI. For
animals with cTnI concentrations above 0.24 ng/mL,
A
B
Fig 1. Serum cTnI (A) and cTnT (B) concentrations of 42 dogs
with systemic inﬂammation (nonsurvivors and survivors) and
healthy control dogs. Geometric mean concentrations (A) for
Gaussian and medians (B) for non-Gaussian data are shown as
horizontal lines. Signiﬁcant diﬀerences between groups are
symbolized with *(receiver operating characteristic curve analysis
with a 95% conﬁdence interval not including .5), o(two-tailed
t-test), and x(Wilcoxon Signed Rank test).
Fig 2. The prognostic contribution of cTnI to the acute patient
physiologic and laboratory evaluation (APPLE) score in 42 dogs
with systemic inﬂammation. Dots represent survivors, and crosses
represent nonsurvivors. The vertical line represents the optimal
predictive cut-oﬀ for the APPLE score (35) identiﬁed by the
receiver operating characteristic (ROC) analysis. Dogs to the left
of this line were predicted to survive by the APPLE score, and
those to the right were predicted to die. The horizontal line rep-
resents the optimal predictive cut-oﬀ for cTnI (0.24 ng/mL) iden-
tiﬁed by the ROC analysis. Dogs below this line were predicted
to survive by cTnI, and those above were predicted to die. The
dark gray zone represents dogs predicted to die according to an
agreed prediction of mortality of APPLE and cTnI. The light
gray zone represents dogs predicted to survive by either APPLE
or cTnI.
Table 1. Prognostic capacity of the established canine
prognostic composite scores and cardiac troponins in
42 critically ill dogs with systemic inﬂammation evalu-
ated by the analysis of receiver operating characteristic
curves (ROCs).
Variable AUC-ROC 95% CI of AUC-ROC
Severity score APPLE* 0.776 [0.621; 0.889]
SPI2 0.610 [0.447; 0.756]
Cardiac marker cTnI* 0.801 [0.649; 0.907]
cTnT* 0.790 [0.637; 0.900]
AUC-ROC, area under the receiver operating characteristic
curve; CI, conﬁdence interval; APPLE, acute patient physiologic
and laboratory evaluation; SPI2, survival prediction index; cTnI,
cardiac troponin I; cTnT, cardiac troponin T.
*Indicates signiﬁcant prognostic capacity.
4 Langhorn et al
the mortality rate was 45.8% whereas it was 0% for
animals with concentrations below the cut-oﬀ.
One measurement of TNF-a was missing because of
insuﬃcient sample material. For TNF-a and MCP-1
there was a signiﬁcant diﬀerence between dogs with
systemic inﬂammation (TNF-a: 10.10 [6.36–23.35]
pg/mL; MCP-1: 656.4 [104.6–1,609] pg/mL) and con-
trol dogs (TNF-a: 8.17 [6.26–9.42] pg/mL; MCP-1:
110.2 [94.69–198.9] pg/mL), however, no diﬀerence
was found between nonsurvivors (TNF-a: 10.52 [7.57–
18.41] pg/mL; MCP-1: 743.7 [193.6–1,506] pg/mL) and
survivors (TNF-a: 10.1 [6.36–23.35] pg/mL; MCP-1:
591.8 [104.6–1,609] pg/mL) (Fig 3D,E). For IL-15 and
IL-18 there was no signiﬁcant diﬀerence between dogs
with systemic inﬂammation (IL-15: 28.73 [<14.8–1,738]
pg/mL; IL-18: 69.63 [<4.6–1,689] pg/mL) and control
dogs (IL-15: 74.12 [24–307.5] pg/mL; IL-18: 89.22
[4.6–658] pg/mL), however, a signiﬁcant diﬀerence was
found between nonsurvivors (IL-15: 16 [<14.8–457.2]
pg/mL; IL-18: 26.71 [<4.6–293.5] pg/mL) and survivors
(IL-15: 60.23 [<14.8–1,738] pg/mL; IL-18: 79.39 [<4.6–
1,689] pg/mL) (Fig 3B,C). For IL-10 there was a
signiﬁcant diﬀerence between dogs with systemic
inﬂammation (8.5 [<1.6–145.6] pg/mL) and control
dogs (all <1.6 pg/mL) as well as between nonsurvivors
(14.33 [<1.6–98.64] pg/mL) and survivors (7.05 [<1.6–
145.6] pg/mL) (Fig 3A). A signiﬁcant correlation was
found between cTnI and the cytokines IL-15
(r = 0.48, Spearman, P = .012) and IL-10 (r = 0.46,
Pearson, P = .0023), but no correlation was found
with TNF-a (r = 0.06, Spearman, P = .71), IL-18
(r = 0.16, Pearson, P = .32), or MCP-1 (r = 0.06,
Spearman, P = .71).
IL-10, IL-15, and IL-18 were found to be signiﬁcant
prognosticators whereas TNF-a and MCP-1 were not
(Table 2). Only IL-15 contributed signiﬁcantly to the
combined prognostic model of cTnI and APPLE
(P = .024), and cTnI lost its signiﬁcance when IL-15
was added to the model (P = .16).
Discussion
This study documents a clinically important degree
of myocardial cell injury occurring in dogs with sys-
temic inﬂammation and without primary cardiac
disease. Presence of myocardial injury was predictive
of short-term survival, and cTnI as a marker of myo-
cardial injury contributed independently to the estab-
lished prognostic composite score, APPLE, by
providing additional prognostic speciﬁcity without
compromising prognostic sensitivity. The inﬂammatory
cytokine IL-15 was correlated with cTnI and identiﬁed
as a signiﬁcant coexplanatory factor for the prognostic
value of cTnI.
The importance of the heart in critical disease is
hardly surprising. However, although objective mark-
ers of injury and function for several other organs
have been routinely measured for decades, no cardiac
marker has been a part of a routine work-up in criti-
cally ill dogs. It seems from the ﬁndings of this study
that the cardiac troponins, especially cTnI, may be
useful for this purpose. The superiority of cTnI over
cTnT in this study may be because of the fact that,
although they supply similar information, cTnI levels
generally increase with less severe disease than those of
cTnT, suggesting that cTnI is a more sensitive marker
of myocardial injury.23,24 The reason for this diﬀerence
in release is unknown, but may be because of a diﬀer-
ence in protein size and molecular weight or the fact
that cTnI may be degraded into fragments after the
brief periods of myocardial ischemia.25,26 In cases of
irreversible myocardial injury, it has also been specu-
lated that cTnT may have a structurally closer binding
to the tropomyosin chain than cTnI.24
Human studies have revealed that the presence of
myocardial injury is associated with increased morbid-
ity and mortality, though clinically it is often unrecog-
nized.8,9 In fact, patients with increased troponin
concentrations can have similar clinical characteristics
as those without evidence of cardiac injury.9 Consider-
ing that cardiac troponins are primarily used in the
diagnosis of AMI, it is notable that mortality for criti-
cally ill patients with myocardial injury can be as high
as or higher than that of patients in whom cardiac tro-
ponins were increased because of a primary cardiac
disease or AMI.8,15,27 This is even more interesting
when it is considered that patients with clinically
unrecognized cardiac injury generally have signiﬁcantly
lower concentrations of cTnI than those with diag-
nosed AMI.8,28 Consequently, it seems that the pres-
ence of myocardial injury in itself rather than just the
degree of injury accounts for a worse prognosis.
In several human studies, cTnI in critically ill
patients remained an independent prognosticator even
after stratifying for illness severity by use of a severity
score.13,17 As is the case for veterinary severity scores,
human severity scores such as APACHE and SAPS
evaluate hemodynamic changes rather than the status
of the heart itself, and it may be argued that myocar-
dial injury, thus not accounted for by the scores,
supplies additional prognostic information.7,13 The
contribution to the prognostic capacity of the APPLE
score by cTnI in this study was highly signiﬁcant. The
eﬀect of cTnI was to improve the prognostic speciﬁcity
of the model. As the model’s prognostic sensitivity was
not compromised, it may be of value to include a
marker of myocardial injury in prognostic severity
scores in the future. It is also noteworthy that the dogs
included in this study had received varying degrees of
volume resuscitation before ICU admission. The prog-
nostic capacity of the cardiac markers was veriﬁed in
spite of this possible interference, thereby further
strengthening their use in a clinical setting.
Although the APPLE score in itself was a signiﬁcant
prognosticator in this study, surprisingly, SPI2 was
not. The cohort of dogs in this study had a survival
rate of 73.8% which is within the range of survival
rates for which the SPI2 was validated.4 However, this
cohort was selected based on the presence of systemic
inﬂammation, and all dogs without evidence of sys-
temic inﬂammation were excluded. As dogs with sys-
temic inﬂammation were included in the construction
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A B
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E
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Fig 3. Serum interleukin (IL)-10 (A), IL-15 (B), IL-18 (C), monocyte chemo-attractant protein-1(MCP-1) (D), and tumor necrosis
factor-a (TNF-a) (E) concentrations of critically ill dogs with systemic inﬂammation (n = 42) and healthy control dogs (n = 8) as well as
of survivors and non-survivors. Geometric mean of concentrations (B, C) for Gaussian and medians (A, D, E) for non-Gaussian data
are shown as horizontal lines. Signiﬁcant diﬀerences between groups are symbolized with *(receiver operating characteristic curve analy-
sis with a 95% conﬁdence interval not including .5), x(Wilcoxon Signed Rank test), and + (Mann–Whitney U-test).
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of both the SPI2 and the APPLE score,3,4 we used the
scores in a patient group for which the scores have
already been validated. Nevertheless, both scores were
constructed with a less selected ICU population, giving
a possible explanation for the reduced performance of
the scores in these cohort when compared to construc-
tion and validation cohorts.
Prognostic composite scores assist clinicians in
supplementing their clinical judgment with objective
measures of patient illness and have been shown to
improve clinicians’ accuracy of survival prediction.29,30
Optimizing the predictive sensitivity and speciﬁcity of
such scores is therefore desirable, and this study identi-
ﬁes a possible need for inclusion of the status of the
myocardium in prognostic scoring. cTnI in itself as
well as the APPLE score had an excellent negative pre-
dictive value, but a less optimal positive predictive
value. This may be because of the fact that myocardial
injury might be reversible in inﬂammatory diseases.
Reversible myocardial depression associated with
sepsis has been recognized in 40–50% of people with
this disease,31,32 and in fact many of these people sur-
vive.33 Reversible myocardial injury has been explained
by several theories. One theory advocates cytokine-
mediated myocardial cell injury leading to myocardial
“cell membrane gaps” with leakage of troponins into
the extracellular ﬂuid.6,14,16 Another theory suggests
reversible ischemia induced by an activated clotting
system in sepsis or SIRS causing microcirculatory
thrombosis, a theory that was rejected in a recent
study.34 Finally, it has been postulated that reversible
myocardial injury may be because of incomplete apop-
tosis.35,36 Most likely, it is a combination of several
factors. The theory of cytokine-mediated myocardial
injury has gained most of the attention in research.
Experimental studies indicate that cytokines such as
TNF-a may lead to an increased permeability of the
cardiomyocyte membrane for macromolecules such as
the troponins.37,38 Cytokines are also thought to
mediate decreased cardiac contractility39 which often
accompanies sepsis. In 1 study of experimental
endotoxemia, however, increased TNF-a, IL-6, and IL-8
were not followed by an increase in cTnI, and it was
speculated that a longer proinﬂammatory mediator
exposure or a concurrent exposure to changes in addi-
tional cytokine concentrations were necessary for car-
diac injury to take place.14 In this study, TNF-a was
not correlated with cTnI or cTnT and was not a signif-
icant prognosticator in itself. The cytokines IL-10,
IL-15, and IL-18, however, were signiﬁcant prognosti-
cators. IL-15 remained signiﬁcant in a model combin-
ing the APPLE score and cTnI, and, interestingly,
cTnI lost its signiﬁcance when IL-15 was added to the
model. This coexplanatory correlation as a predictor
of outcome may be coupled to etiology and supports
the suggested contribution of cytokines to myocardial
injury. Experimental evidence exists of IL-15 treatment
having a beneﬁcial eﬀect in mice with virus-induced
myocarditis40 which further supports our ﬁndings of
signiﬁcantly higher cTnI concentrations and lower
IL-15 concentrations in nonsurvivors compared to
survivors. Further studies will have to be conducted to
elucidate the possible etiological correlation.
An important limitation of this study was the fact
that the model created combining the APPLE score
with cTnI was not validated in a separate cohort of
dogs. A multicenter study including a larger cohort of
dogs with systemic inﬂammation would be valuable
for further evaluation of the beneﬁt of including mark-
ers of myocardial injury in composite severity scores.
Secondly, a source of error inherent to veterinary
survival studies was created when decisions were made
to include dogs that were euthanized rather than only
dogs that died naturally. Some nonsurvivors might, in
fact, have survived, had treatment been continued.
APPLE and SPI2, the 2 diagnosis-independent severity
scores validated for use in dogs, both include eutha-
nized dogs, but SPI2 attempts to minimize this error
by only including dogs that are euthanized because of
a grave prognosis for survival.3,4 Accordingly, these
criteria were applied to this study as well. Thirdly, it
cannot be excluded that a degree of mechanical cardiac
injury may have occurred in the 5 dogs with
polytrauma, causing potential bias. The dogs were
equally distributed among the population with regard
to cTnI concentrations and APPLE scores, exclusion
from statistical analysis did not change any of the spe-
ciﬁc ﬁndings (data not shown), and as inﬂammatory
cardiac injury was likely to be involved, these dogs
were not excluded from the study. A 4th limitation
was the fact that the analytical sensitivity of the assays
for cTnT and IL-10 was insuﬃcient, where the value
of the detection limit was assigned to several samples
with a risk of violation of statistical assumptions.
However, as graphical examination of the data for
both variables revealed a considerable diﬀerence
between dogs with systemic inﬂammation and control
dogs, the test results were considered valid. Finally, to
ensure exclusion of primary cardiac disease, it is possi-
ble that a few dogs with decreased contractility were
excluded as it may resemble mild DCM. This may
have reduced the size of our study population, but was
not thought to cause a bias as it only strengthened
our certainty of a cardiac disease-free population.
Nevertheless, a few study-eligible dogs with critical
Table 2. Prognostic capacity of various cytokines in
42 critically ill dogs with systemic inﬂammation evalu-
ated by analysis of receiver operating characteristic
curves (ROCs).
Variable AUC-ROC 95% CI of AUC-ROC
Cytokine IL-10* 0.679 [0.517; 0.814]
IL-15* 0.723 [0.563; 0.849]
IL-18* 0.694 [0.532; 0.826]
MCP-1 0.575 [0.413; 0.726]
TNF-a 0.503 [0.343; 0.663]
AUC-ROC, area under the receiver operating characteristic
curve; CI, conﬁdence interval; IL, interleukin; MCP-1, monocyte
chemo-attractant protein-1; TNF-a, tumor necrosis factor-a.
*Indicates signiﬁcant prognostic capacity.
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illness-induced myocardial dysfunction may have been
wrongly excluded, but valvular disease was, by far, the
most common cause of exclusion.
In conclusion, markers of myocardial injury were
found to be predictive of 28-day case fatality in criti-
cally ill dogs with systemic inﬂammation and without
a primary cardiac diagnosis. cTnI signiﬁcantly contrib-
uted to the prognostic composite score, APPLE, by
improving prognostic speciﬁcity without compromising
prognostic sensitivity and thus may be valuable in con-
struction of future severity scores. Finally, IL-15 might
play a role in the sequence of events leading to
myocardial injury in these dogs.
Footnotes
a Langhorn R, Oyama MA, King, LG, et al. Canine cardiac
troponin I signiﬁcantly complements established prognostic
composite score in dogs with systemic inﬂammation. J Vet
Intern Med 2012;26:713 (abstract)
b Scil vet ABC hematology analyzer; Horiba ABX, Northamp-
ton, UK
c Vitros 350 chemistry analyzer; Orthoclinial Diagnostics, John-
son and Johnson, Rochester, NY
d ADVIA Centaur CP TnI-ultra; Siemens Healthcare Diagnostics
Inc, Tarrytown, NY
e Elecsys hs-TnT; Roche Diagnostic Corporation, Indianapolis,
IN
f Canine C-reactive Protein; LifeDiagnostics, West Chester, PA
g Quantikine CATA00; R&D Systems Inc, Minneapolis, MN
h CCYTO-90K; Millipore Corporation, Billerica, MA
i Luminex 200; Luminex Corporation, Austin, TX
j GraphPad Prism 5.01 for Windows; GraphPad Software, San
Diego, CA
k MedCalc 6.00.012; MedCalc Software, Mariakerke, Belgium
l SAS 9.2; SAS Institute Inc, Cary, NC
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